Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 320 participants.

Also called NCT05321875

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 320 participants (planned count) (from the registry)
Sponsor
Cristina Avendaño Solá (from the registry)
Registry
  • NCT NCT05321875
  • EudraCT 2021-004577-30
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05321875. Randomized; quadruple masking; primary purpose prevention. Start 2022-06-02 (actual); primary completion 2026-06-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)
Acronym
EARLY-GENE
Condition
Cardiomyopathy, Dilated
Intervention (Drug)
Candesartan
Lead sponsor
Cristina Avendaño Solá (class: other)

Record details

Record id
cardio:ct-nct05321875
Content hash
43f26f50396fecedfbdf1cf8539303e67545248556c86cf79e58b7c2de45a8a6